‘We’re going to have to go back to square one’: Man arrested after allegedly killing ex-girlfriend’s child
A Florida man has been arrested after reportedly killing his ex-fiancee’s child, police said.
John Anthony DeLuca, 26, was arrested Tuesday after the alleged incident happened at his home in the Orlando suburb of Boca Raton, Florida.
Police said the incident took place after DeLucas allegedly assaulted his ex in their home last month.
Police identified the woman who was killed as Katelyn P. Pappas.
According to police, DeLuces allegedly took his girlfriend’s child and then attempted to take the child to another location.
Authorities said DeLucis later told police he had a gun in his possession, but did not specify whether the gun was loaded or not.
Police say DeLucs was taken to the Polk County Jail on charges of murder, aggravated assault and tampering with evidence.
UAE: The UAE has long been a hotbed for recruiting overseas talent, but the country has been taking steps to tighten the recruitment process to attract and retain its brightest talent, a senior UAE government official said on Wednesday.
The country needs to recruit and retain the best and brightest talent for the UAE, he said, as the UAE seeks to diversify its workforce.
This year, the government has set targets to recruit 5,000 to 10,000 foreign-trained and trained-up staff, the official told Reuters.
To ensure the UAE has a strong recruitment process, the chief minister and government officials are working to ensure that all employees are eligible for a pay rise as well as a salary increase, he added.
However, there are several issues that need to be addressed, he told Reuters, including the high number of foreign-based workers.
There is a lack of clarity around the number of qualified foreign workers in the sector and their salary, he stressed.
One issue, he noted, is that some of the foreign workers have been recruited through dubious means, such as hiring agents.
“The recruitment of foreign workers has not been done properly,” the official said.
For instance, some foreign workers are not being given a fair share of the pay rise.
He also said there are problems in the recruitment of domestic staff to fill vacancies in key administrative positions, such in social services.
He said the government is working on measures to improve the process for finding foreign workers.
A US$1 billion US-made vaccine has been approved by the US Food and Drug Administration for use in adults with COPD.
The FDA confirmed the approval on Monday.
Dr David Yaffe, a professor of preventive medicine at the University of California, San Francisco, said that although the vaccine could be used in people with COPE, it was likely to have a limited use in people who already have COPD because of the severity of the disease.
“The benefits to the population are so much greater than the risks,” Dr Yaffe said.
“What this vaccine does is prevent a lot of the inflammation that we see in COPD.”
A number of countries have introduced their own vaccines in recent years, but only one of those was approved by US regulators.
Vaccines approved in Australia and the Netherlands have also shown promising results in reducing COPD mortality and COVID-19 rates.
“It’s a big leap forward in the field of preventive medicines,” Dr Zaki Makhmud, a senior medical scientist at the Institute for Infectious Diseases (IID) in Dubai, said.
He said there were “no indications” that COPD patients would benefit from the new vaccine.
The US National Institutes of Health (NIH) and the National Cancer Institute (NCI) have spent the past few years developing the vaccine and it is expected to be approved by both bodies by late 2020.
The new vaccine has also been approved for use by the EU.
“We have a very clear plan to be able to provide a vaccine in 2020,” Dr Makhud said.
The new vaccines will be delivered in a similar way to the first vaccines, Dr Mkhmud said.
“We’re talking about very high quality vaccines and that means there are a lot fewer side effects.”
The US vaccine has received more than $1 billion in funding and will be manufactured by Gilead Sciences, which is based in Menlo Park, California.
The company said it would start shipping its vaccine to the US in January 2021, and would deliver it by the end of the year.
It said it was committed to delivering the vaccine within three years.
The World Health Organization estimates that the virus causes approximately 200,000 deaths a year worldwide.
According to the WHO, there is a 25 per cent chance of contracting COVID in an individual, and an additional 10 per cent of cases could result in death.
Since its introduction in 2002, the virus has been the cause of several epidemics, most notably in the US, but it is still relatively rare in Europe and North America.